292 results about "Viral replication" patented technology

The invention relates to the technical field of molecular biology, in particular to a multichannel virus reporting system based on TAT trans-activation. The invention relates to a multichannel virus reporting system based on TAT trans-activation. The multichannel virus reporting system comprises an activated virus and a reporting cell, the activated virus is a human enterovirus A71 for expressing TAT protein; the reporter cells are cells transfected with reporter plasmids; the reporter plasmid comprises an LTR sequence and a plurality of reporter genes which are started to express by the LTR sequence. When the virus is activated to infect the reporter cell, the TAT protein carried by the virus enters the reporter cell to activate the expression of the downstream reporter gene, and the expression level of the reporter gene can reflect the virus replication condition, so that the screening or mechanism research of related antiviral drugs can be realized. According to the technical scheme, the technical problem that the flexibility, stability and high-throughput screening adaptability of a virus reporting system in the prior art are not ideal can be solved, and the virus reporting system has ideal popularization and application prospects.

The present invention uses ex vivo human airway cultures to assess the human transmissibility and replication competence of influenza and coronavirus strains. By comparing pandemic influenza A subtype H1N1 and highly pathogenic avian influenza H5N1 as reference strains, the transmissibility risk of various viruses was evaluated and categorized. Additionally, an in vitro model evaluated virus-induced impairment of alveolar fluid clearance (AFC) as an indicator of disease severity. The study revealed correlations between bronchus viral replication, human transmission, AFC impairment, and clinical disease severity across different influenza and coronavirus strains.

The present invention relates to a conjugate for inhibiting viral replication, a preparation method therefor, and use thereof. The conjugate comprises a dimer or trimer of a portion that inhibits influenza virus neuraminidase (e.g. zanamivir, peramivir, oseltamivir, or an analog thereof), the dimer or trimer being conjugated to an Fc domain monomer, an Fc domain, an Fc-binding peptide, an albumin, or an albumin-binding peptide. The conjugate can be used to treat viral infections (e.g., influenza virus infections).

The invention belongs to the technical field of medicines, and provides a compound for inhibiting virus replication and application of the compound in preparation of a medicine for resisting feline infectious peritonitis virus (FIPV). The number of the compounds provided by the invention is 10, and the 10 compounds have obvious inhibiting and blocking effects on a 1-bit ribosome frameshift process of the FIPV, and can effectively inhibit the replication and proliferation of the FIPV. The ten compounds can be used for treating and preventing feline infectious peritonitis diseases caused by FIPV infection; the compound disclosed by the invention can be used for preparing anti-FIPV medicines and medicines for treating and preventing feline infectious peritonitis diseases caused by FIPV infection, and has a wide application prospect.

The invention belongs to the technical field of biological pharmacy, and particularly relates to an anti-coronavirus medicine and application. According to the application disclosed by the embodiment of the invention, experiments prove that the punicalagin and the punicalagin respectively have strong binding force to SARS-CoV-2 main protease Mpro and have a remarkable inhibition effect on SARS-CoV-2 virus replication, so that the punicalagin and the punicalagin can be used as novel SARS-CoV-2 inhibitors. Therefore, punicalagin and / or punicalagin can be used for preparing products for inhibiting novel coronavirus.

This article provides a combination of compounds that can inhibit influenza virus replication, reduce influenza virus load, and / or treat influenza.

The invention belongs to the technical field of medicines, and discloses application of a compound in prevention and treatment of coronavirus infection and / or diseases caused by coronavirus. In particular discloses application of one or more of G96-69, G96-70, G102-35, G110-74, G115-49 and G118-1 in prevention and treatment of coronavirus infection and diseases caused by the coronavirus, improvement of symptoms caused by the coronavirus and in-vitro inhibition of coronavirus replication in a non-treatment destination, and the G96-69, the G96-70, the G102-35, the G110-74, the G115-49 and the G118-1 have relatively good effects in the aspect of resisting the coronavirus. EC50 for inhibiting mouse hepatitis virus MHV is less than 6 [mu] M; the EC 50 of the HCoV-OC43, the EC 50 of the HCoV-229E and the EC 50 of the HCoV-NL63 which are inhibited by the G96-69 and the G96-70 are all smaller than 2 [mu] M.

This invention generally relates to a novel RNA / mRNA production and amplification method using viral RNA replicase and / or RNA-dependent RNA polymerase (RdRp) enzymes as well as the associated mRNAs thereof. The present invention can be used for manufacturing and amplifying all varieties of RNA / mRNA sequences carrying at least an RdRp-binding site in the 5′- or 3′-end, or both. The RNA / mRNA so obtained is useful for not only producing mRNA vaccines and / or RNA-based medicines but also for generating the mRNA-associated proteins, peptides, and / or antibodies under an in-vitro as well as in-cell translation condition. Principally, the present invention is a novel RNA replicase-mediated RNA / mRNA amplification method, namely Replicase Cycling Reaction (RCR). The RNA replicases involved in RCR include but not limited to viral and / or bacteriophage RNA-dependent RNA polymerases (RdRp), particularly coronaviral and hepatitis C viral (HCV) RdRp enzymes.

The present invention pertains to the use of a vaccine based on an alphavirus RNA replicon particle (αRP) vector encoding an antigen of an IAV-S for the passive vaccination of piglets against a pathogenic infection with swine influenza virus.

To provide a method for propagating a recombinant influenza B virus, and a host cell.SOLUTION: A method for propagating a recombinant influenza B virus comprising a mutant BM2 gene having a specific sequence comprises: contacting a host cell with the recombinant influenza B virus; and incubating the host cell for a sufficient time and under conditions suitable for viral replication; where the host cell is an MDCK cell or a Vero cell expressing functional BM2 or chimeric M2-BM2 proteins.SELECTED DRAWING: None

This invention discloses the application of the DNAL1 gene as a target in screening drugs for the prevention and treatment of Zika virus or dengue virus type 2 infection, specifically the application of screening drugs for the prevention and / or treatment of Zika virus or dengue virus type 2 infection with the aim of inhibiting or knocking out the DNAL1 gene. The invention has found that the DNAL1 gene is a key host factor promoting the replication of Zika virus or dengue virus type 2, and that inhibiting the DNAL1 gene through siRNA or knocking out the DNAL1 gene through CRISPR / Cas9 can inhibit the replication of Zika virus or dengue virus type 2. The DNAL1 gene is a potential host factor for flaviviruses, and this invention provides a potential target for the prevention and / or treatment of Zika virus or dengue virus type 2 infection.

This disclosure relates to a method for preparing intermediates useful for preparing compounds that inhibit the function of human immunodeficiency virus (HIV) during the viral replication cycle, such as by disrupting the function of the HIV capsid shell. [Formula 1] JPEG2026524821000058.jpg39145

The present invention relates to vaccination against animal pathogens using alpha virus-replicon RNA particles and oil adjuvants. To vaccines and kits comprising said replicon particles and said oil adjuvant. The invention also relates to methods and uses for preparing and using the vaccine and the components of the kit.

Methods and compositions are described for modulating the activity of a poxvirus polymerase by modulating the assembly and / or interaction of one or more subunits of the poxvirus polymerase.

The present application provides the use of raltitrexed in the manufacture of a medicament for the treatment of diseases caused by adenovirus infection, including but not limited to respiratory tract infection, gastrointestinal infection and keratitis caused by adenovirus. When raltitrexed was tested for its anti-adenovirus activity at the cellular level, using a viral infection dose of 100 TCID50, the viral infectivity was determined on a human non-small cell lung cancer cell line (A549 cell) model, and the results showed that raltitrexed had a significant inhibitory effect on adenovirus, with an EC 50 = 8.98 nM, a CC 50 > 187.5 nM, and it was found that it had a significant inhibitory effect on the entry of the virus into the cell; and in the hDSG2 mouse model, a significant inhibitory effect of raltitrexed on viral replication was also observed. Therefore, raltitrexed can be used to treat diseases caused by adenovirus infection.

A cassette for the delivery of one or more mRNA is provided, the cassette comprising a 5' UTR, a Nodamura replicon, a ribosomal skipping polynucleotide, the one or more mRNA, a plant virus assembly origin polynucleotide ("OAS"), and a 3' UTR. In one aspect, the cassette further comprises a 5'mRNA cap. In a yet further aspect, the cassette does not comprise a poly A tail.

Described herein is an oncolytic herpes simplex virus, G47ΔhIL12A, which is G47Δ containing a cassette expressing a transgene, e.g., human IL-12, driven by a spontaneously arising genetically altered HCMV immediate-early (IE) enhancer / promoter. This virus has augmented (A) production of the transgene and increased virus replication while retaining safety. Also provided are methods of use thereof for treating cancer, e.g., glioblastoma (GBM) and triple-negative breast cancer (TNBC).

The present invention relates to a circular RNA for targeted inhibition of fish neural necrosis virus replication, as well as a preparation method and application thereof. The circular RNA is NNV-circRNA-1, whose nucleotide sequence is shown in SEQ ID NO:1. The circular RNA is prepared by cyclizing linear NNV-circRNA-1 with T4 RNA ligase 1 and then removing residual linear RNA in the reaction system using RNase R enzyme. The circular RNA prepared by the present invention has good stability and high purity. NNV-circRNA-1 has a strong binding ability with NNV-RdRp protein, can effectively inhibit the replication of NNV virus, and can be used in the preparation of vaccines, antiviral drugs and other biological immune products for fish neural necrosis virus in the field of aquaculture.

The present application relates to viral sensitizers. More specifically, the present application relates to compounds of Formula (I), as well as methods of using such compounds as viral sensitizers, specifically for increasing permissiveness of a cell to the production of virus from reverse genetics systems, replicating viruses and increasing transduction.

The present invention relates to processes for preparing intermediates useful in the preparation of compounds that inhibit human immunodeficiency virus (HIV) function (e.g., disrupt HIV capsid function) during the viral replication cycle.

The invention relates to the field of biotechnology and targeted therapy, in particular to a recombinant construct, a recombinant oncolytic virus and construction and application of the recombinant oncolytic virus. The virus takes a wild poxvirus genome as a skeleton, thymokinase TK genes are deleted through homologous recombination, and a poxvirus P-se / l promoter is used for promoting expression of a CD19 membrane localization antibody. The constructed recombinant oncopoxvirus aCD19-TM-OVV can improve the infection efficiency and gene delivery efficiency on B lymphoma in a CD19 antigen target-dependent manner, promote virus replication of the oncopoxvirus in CD19 positive B lymphoma cells, and significantly enhance the tumor growth inhibition effect on the CD19 positive B lymphoma cells in vitro and in mouse B lymphoma models.

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

Provided herein are RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof. Also provided herein are compositions that include RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof, and lipids. RNA molecules and compositions including them are useful for inducing immune responses.

The invention discloses an influenza reporter virus carrying a fluorescent RNA aptamer and a construction method and application thereof, and the influenza reporter virus carrying the fluorescent RNA aptamer is obtained by introducing a termination codon TAA into the 328th nucleotide of an ORF region of an NS1 gene on the basis of a genome of an influenza A virus and terminating in advance, then introducing a terminating codon TAA into the 328th nucleotide of the ORF region of the NS1 gene of the influenza A virus; original nucleotides at the 328-480 sites are replaced by forward or reverse RNA aptamers, and the RNA aptamer is obtained. The influenza reporter virus carrying the fluorescent RNA aptamer constructed by the invention also has the characteristics of good virus replication ability, high RNA imaging sensitivity and good specificity on the basis of stable inheritance, can be used for real-time visual observation of virus RNA, and is used for research on virus replication cycle and molecular mechanism related to the virus RNA. Besides, the construction method of the influenza reporter virus carrying the fluorescent RNA aptamer can also be applied to construction of RNA fluorescent reporter viruses of other subtype influenza viruses such as H3N2 and H5N1, and an important tool is provided for real-time tracing of corresponding virus RNA.

The invention uses ex vivo human airway cultures to assess the transmissibility and replication ability of influenza and coronavirus strains. By comparing the pandemic influenza A H1N1 and the highly pathogenic influenza A H5N1 as reference virus strains, the spreading risks of various viruses are evaluated and classified. In addition, an in vitro model is used to assess the degree of alveolar fluid clearance (AFC) impairment caused by the virus as an indicator of the severity of the disease. The research reveals the relevance among the virus replication ability, human transmission, AFC damage degree and clinical disease severity of different influenza and coronavirus strains in bronchus.

The invention discloses an application of estramustine sodium phosphate (EMP) in preparation of a drug for treating rotavirus, and discovers that the estramustine sodium phosphate (EMP) can significantly inhibit replication of rotavirus and can play an excellent anti-rotavirus effect at a lower IC50; as the biological safety of the EMP is excellent, it is found that the EMP can almost completely inhibit rotavirus replication within the safe concentration, and it is found that the EMP not only significantly inhibits transcription of rotavirus, but also can reduce expression of VP6 protein. Thus, EMP can be used to treat rotavirus.

The invention relates to the field of medicines, in particular to a YDT compound as well as a preparation method and application thereof. The invention provides a YDT compound or a pharmaceutically acceptable salt and a metabolite thereof. The YDT compound has a structure as shown in a formula 1, formula 1. According to the invention, SAR405 is used as a core skeleton, in order to enhance in-vivo absorption or reduce the removal rate of SAR405, a ring structure and substituent groups on the ring are modified and replaced, and finally a brand new compound with different skeleton structures and modification groups is provided. The SAR405 can be used as a host-targeted antiviral drug for blocking virus replication by inhibiting virus-host interaction, and exerts the in-vivo antiviral ability that SAR405 cannot have. Therefore, the VPS34 autophagy inhibitor can be applied to preparation of a medicine for preparing a VPS34 autophagy inhibitor, preparation of a medicine for resisting the SARS-CoV-2 virus and preparation of a medicine for treating pneumonia caused by the SARS-CoV-2 virus.

The invention belongs to the technical field of medicines, and particularly relates to pyrrolo [2, 3-d] pyrimidine compounds of aryl fragments and piperidine fragments as well as a preparation method and application of the pyrrolo [2, 3-d] pyrimidine compounds. The pyrrolo [2, 3-d] pyrimidine compound containing the aryl fragment and the piperidine fragment is an HIV-1 reverse transcriptase inhibitor, and the pyrrolo [2, 3-d] pyrimidine compound further comprises pharmaceutical salt, hydrate and solvate of the pyrrolo [2, 3-d] pyrimidine compound, polycrystal or eutectic of the pyrrolo [2, 3-d] pyrimidine compound, and precursors and derivatives with the same biological functions of the pyrrolo [2, 3-d] pyrimidine compound. The invention also relates to a preparation method of the compound and application of a composition containing one or more of the compounds in related medicines for treating AIDS and the like. The result of an in-vitro cellular level anti-HIV-1 activity experiment shows that the micromolecule has relatively strong anti-HIV-1 biological activity, can remarkably inhibit virus replication in MT-4 cells infected by HIV-1 viruses, and has relatively low cytotoxicity.

The invention belongs to the technical field of virus and gene engineering, and particularly relates to an expression vector of a respiratory syncytial virus (RSV) ON1 genotype consensus sequence strain and an editing strain, a reverse genetic manipulation system and an application of the reverse genetic manipulation system of the respiratory syncytial virus ON1 genotype consensus sequence strain and the editing strain of the RSV ON1 genotype consensus sequence strain and the editing strain of the respiratory syncytial virus ON1 genotype consensus sequence strain. According to the invention, an RSV-ON1 genotype consensus sequence strain is firstly constructed and saved, on the basis, 72 nucleotides which are repeatedly inserted into a G gene of the consensus sequence strain are removed through a gene editing technology, and two strains with different virus G gene sequences are obtained. According to the invention, through construction of RSV infectious clone edited by RSV-ON1 genotype G gene and rescue of the two strains, a fast, simple and accurate RSV reverse genetic system is constructed, and the RSV reverse genetic system can be applied to research on RSV in-vitro virus replication mechanism and pathogenesis and neutralizing antibody immune escape. A etiological technical platform is provided for research, development and evaluation of RSV vaccines, antibodies, drugs and the like.

The present application belongs to the field of genetic engineering and biological medicine technology, and particularly relates to a biomaterial for regulating HTRA1 gene expression and application thereof in antiviral. Specifically, the present application finds that inhibiting HTRA1 gene can significantly promote replication of H13N2 subtype influenza virus, thereby promoting infection of H13N2 subtype influenza virus, while overexpression of HTRA1 can effectively inhibit replication of H13N2 subtype influenza virus, reduce virus titer, and thus improve the ability to resist influenza virus infection, so that the HTRA1 gene can be used as a key target for regulating replication of H13N2 subtype influenza virus, and thus has good practical application value.